Clinical outcomes in psoriatic arthritis: A systematic literature review

Many outcomes have been proposed in the assessment of psoriatic arthritis (PsA). The Outcome Measures in Rheumatology (OMERACT) core set for PsA evaluation comprises 6 domains: joints, skin, function, pain, patient's global assessment, and quality of life. The objective of this work was to assess reporting of outcomes in PsA, including patient‐reported outcomes (PROs) in recent publications.

[1]  S. Todesco,et al.  MonitorNet: studio italiano osservazionale multicentrico per la valutazione del profilo rischio-beneficio dei farmaci biologici nella pratica clinica reumatologica , 2011 .

[2]  P. Mease,et al.  Patient-reported Outcomes in a Randomized Trial of Etanercept in Psoriatic Arthritis , 2010, Journal of Rheumatology.

[3]  D. Symmons,et al.  Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies , 2010, Arthritis care & research.

[4]  J. Ortonne,et al.  Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial , 2010, BMJ : British Medical Journal.

[5]  A. Sanduzzi,et al.  Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs , 2010, Clinical Rheumatology.

[6]  S. Chimenti,et al.  Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study , 2009, The Journal of dermatological treatment.

[7]  I. Olivieri,et al.  The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. , 2009, Clinical and experimental rheumatology.

[8]  E. Taal,et al.  New insights into the experience of fatigue among patients with rheumatoid arthritis: a qualitative study , 2009, Annals of the rheumatic diseases.

[9]  P. Goupille,et al.  Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions , 2009, Annals of the rheumatic diseases.

[10]  A. Gottlieb,et al.  International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. , 2009, Arthritis and rheumatism.

[11]  D. M. van der Heijde,et al.  Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis , 2009, Annals of the Rheumatic Diseases.

[12]  M. Suarez‐Almazor,et al.  Progress on Incorporating the Patient Perspective in Outcome Assessment in Rheumatology and the Emergence of Life Impact Measures at OMERACT 9 , 2009, The Journal of Rheumatology.

[13]  I. Olivieri,et al.  Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis , 2009, Annals of the rheumatic diseases.

[14]  P. Tugwell,et al.  OMERACT 9 ‒ 9th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials , 2009, The Journal of Rheumatology.

[15]  D. Patrick,et al.  The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. , 2009, Contemporary clinical trials.

[16]  I. Olivieri,et al.  Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic Arthritis , 2009, The Journal of Rheumatology.

[17]  D. Gladman,et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.

[18]  P. Mease,et al.  Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. , 2009, Journal of the American Academy of Dermatology.

[19]  A. Gottlieb,et al.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2009, The Lancet.

[20]  C. Ritchlin,et al.  Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging , 2009, Annals of the rheumatic diseases.

[21]  P. Szodoray,et al.  Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. , 2009, Acta dermato-venereologica.

[22]  A. Holman,et al.  Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis , 2008, Autonomic Neuroscience.

[23]  Y. Leung,et al.  Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis. , 2008, Rheumatology.

[24]  A. Iagnocco,et al.  Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor α , 2008, Annals of the rheumatic diseases.

[25]  J. Bryan,et al.  Effects of a modular behavioural arthritis education programme: a pragmatic parallel-group randomized controlled trial. , 2008, Rheumatology.

[26]  V. Strand,et al.  Health care utilization in patients with spondyloarthropathies. , 2008, Rheumatology.

[27]  R. Scrivo,et al.  Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis , 2008, Annals of the rheumatic diseases.

[28]  C. De Simone,et al.  Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. , 2008, Journal of biological regulators and homeostatic agents.

[29]  M. Aricò,et al.  Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis , 2008, Dermatologic therapy.

[30]  I. Olivieri,et al.  The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy , 2008, Rheumatology.

[31]  D. Gladman,et al.  Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) , 2008, Annals of the rheumatic diseases.

[32]  A. Zwinderman,et al.  A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue , 2008, Annals of the rheumatic diseases.

[33]  F. Manguso,et al.  The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate , 2008, Clinical Rheumatology.

[34]  I. Olivieri,et al.  Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. , 2008, Rheumatology.

[35]  W. Koldingsnes,et al.  Work disability and health-related quality of life in males and females with psoriatic arthritis , 2008, Annals of the rheumatic diseases.

[36]  D. Gladman,et al.  Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). , 2008, The Journal of rheumatology.

[37]  M. Dougados,et al.  Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review , 2008, Annals of the rheumatic diseases.

[38]  W. Koldingsnes,et al.  The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. , 2008, Arthritis and rheumatism.

[39]  A. Kivitz,et al.  A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. , 2007, Seminars in arthritis and rheumatism.

[40]  E. Schwarz,et al.  The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis , 2007, Annals of the rheumatic diseases.

[41]  P. Helliwell,et al.  Sensitivity and specificity of plain radiographic features of peripheral enthesopathy at major sites in psoriatic arthritis , 2007, Skeletal Radiology.

[42]  S. Chimenti,et al.  Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. , 2007, Journal of the American Academy of Dermatology.

[43]  D. Gladman,et al.  International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. , 2007, The Journal of rheumatology.

[44]  D. Gladman,et al.  International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. , 2007, The Journal of rheumatology.

[45]  P. Geborek,et al.  Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register , 2007 .

[46]  G. Cirino,et al.  Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study. , 2007, Rheumatology.

[47]  P. Helliwell,et al.  Measuring dactylitis in clinical trials: which is the best instrument to use? , 2007, The Journal of rheumatology.

[48]  A. Gottlieb,et al.  Consensus on a core set of domains for psoriatic arthritis. , 2007, The Journal of rheumatology.

[49]  M. Genovese,et al.  Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. , 2007, Journal of Rheumatology.

[50]  M. Suarez‐Almazor,et al.  Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. , 2007, The Journal of rheumatology.

[51]  A. Cieza,et al.  Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. , 2007, Arthritis and rheumatism.

[52]  B. Strober,et al.  Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. , 2007, Cutis.

[53]  A. Kimball,et al.  Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. , 2007, Journal of drugs in dermatology : JDD.

[54]  P. Mease,et al.  Efalizumab for the Treatment of Psoriatic Arthritis , 2007, Journal of cutaneous medicine and surgery.

[55]  D. Gladman,et al.  Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. , 2007, Arthritis and rheumatism.

[56]  W. Koldingsnes,et al.  The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study , 2007, Annals of the rheumatic diseases.

[57]  P. Emery,et al.  Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis , 2006, Annals of the rheumatic diseases.

[58]  E. Casado,et al.  Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate , 2006, Annals of the rheumatic diseases.

[59]  J. Papadakis,et al.  Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. , 2006, The Journal of rheumatology.

[60]  D. Gladman,et al.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial , 2006, Annals of the rheumatic diseases.

[61]  D. Gladman,et al.  Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. , 2006, The Journal of rheumatology.

[62]  P. Voulgari,et al.  Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience , 2006, Annals of the rheumatic diseases.

[63]  D. Gladman,et al.  Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial , 2006, Annals of the rheumatic diseases.

[64]  U. Walker,et al.  Analgesic and disease modifying effects of interferential current in psoriatic arthritis , 2006, Rheumatology International.

[65]  D. Cella,et al.  Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[66]  D. Gladman,et al.  Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). , 2005, Arthritis and rheumatism.

[67]  D. Gladman,et al.  Psoriatic arthritis assessment tools in clinical trials , 2005, Annals of the rheumatic diseases.

[68]  A. Tennant,et al.  Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis , 2004, Annals of the rheumatic diseases.

[69]  N. Leidy,et al.  Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[70]  J. Kirwan,et al.  Rheumatology outcomes: the patient's perspective. , 2003, The Journal of rheumatology.

[71]  M. Dougados,et al.  Assessment of enthesitis in ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[72]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[73]  R. Yood,et al.  Guidelines for the management of rheumatoid arthritis: 2002 Update. , 2002, Arthritis and rheumatism.

[74]  I. Haslock,et al.  Development and validation of a self-efficacy scale for use in British patients with rheumatoid arthritis (RASE). , 2001, Rheumatology.

[75]  J. Prochaska,et al.  Understanding the adoption of arthritis self-management: stages of change profiles among arthritis patients , 2000, Pain.

[76]  A. Clarke,et al.  Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. , 2000, The Journal of rheumatology.

[77]  P. Kind,et al.  Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. , 1998, British journal of rheumatology.

[78]  N. Black,et al.  Effect of blinding and unmasking on the quality of peer review: a randomized trial. , 1998, JAMA.

[79]  D. Reda,et al.  Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. , 1996, Arthritis and rheumatism.

[80]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[81]  A. Calin,et al.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.

[82]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[83]  M. Chamberlain,et al.  Functional assessment in ankylosing spondylitis: evaluation of a new self-administered questionnaire and correlation with anthropometric variables. , 1994, British journal of rheumatology.

[84]  S. van der Linden,et al.  Comparison between self-report measures and clinical observations of functional disability in ankylosing spondylitis, rheumatoid arthritis and fibromyalgia. , 1994, Journal of Rheumatology.

[85]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[86]  A Coulter,et al.  Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. , 1993, BMJ.

[87]  Scott Dl.  A simple index to assess disease activity in rheumatoid arthritis. , 1993 .

[88]  C. Kwoh,et al.  Concordance between clinician and patient assessment of physical and mental health status. , 1992, The Journal of rheumatology.

[89]  A. Finlay,et al.  Psoriasis‐an index of disability , 1987, Clinical and experimental dermatology.

[90]  S. Soraci,et al.  Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. , 1983, Arthritis and rheumatism.

[91]  J. Weinberg.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2010 .

[92]  F. Salaffi,et al.  MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice. , 2009, Reumatismo.

[93]  K. Kalunian,et al.  The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. , 2007, The Journal of rheumatology.

[94]  M. Inanç,et al.  Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis , 2006, Clinical Rheumatology.

[95]  D. Gladman,et al.  International spondyloarthritis inter-observer reliability exercise - The inspire study , 2006 .

[96]  D. Gladman,et al.  Assessment of patients with psoriatic arthritis: a review of currently available measures. , 2004, Arthritis and rheumatism.

[97]  G. Langley,et al.  The visual analogue scale: Its use in pain measurement , 2004, Rheumatology International.

[98]  J. Fries,et al.  The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. , 2003, The Journal of rheumatology.

[99]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.

[100]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[101]  D. Scott.  A simple index to assess disease activity in rheumatoid arthritis. , 1993, The Journal of rheumatology.

[102]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[103]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[104]  K. Lorig,et al.  Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. , 1989, Arthritis and rheumatism.

[105]  C. Ekdahl,et al.  Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. , 1988, Scandinavian journal of rheumatology.

[106]  K. Wallston,et al.  The measurement of helplessness in rheumatoid arthritis. The development of the arthritis helplessness index. , 1985, The Journal of rheumatology.

[107]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[108]  E. B. Seligmann.  Laboratory techniques in rabies. Potency-test requirements of the United States National Institutes of Health (NIH). , 1966, Monograph series. World Health Organization.